Phase 1 study of the oral platinum agent satraplatin in combination with capecitabine for the treatment of patients with advanced solid malignancies.
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2012
At a glance
- Drugs Capecitabine; Satraplatin
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Agennix AG
- 27 Mar 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
- 21 Mar 2012 Agennix as trial company and lead trial centre added as reported by ClinicalTrials.gov.
- 21 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.